



OVENTUS™

Oventus: Innovators in Sleep Apnoea Treatment

FNN Investor Presentation

October 11, 2018 – Sydney



About Oventus (ASX: OVN)


Oventus is commercialising its O₂Vent™ and associated technologies to treat Obstructive Sleep Apnoea (OSA)

A photograph of a bed with a light-colored wooden headboard. Three white pillows are arranged against the headboard. The text is overlaid on the image.

Obstructive sleep apnoea...
more than just a poor night's sleep

**OSA impacts the way
people breathe when they
are sleeping.**


**Breathing is briefly
interrupted or becomes very
shallow during sleep.**

A light gray world map with several colored location pins: three blue pins in North America, Europe, and East Asia; one orange pin in Southeast Asia; and one dark blue pin in Australia. The text "Poor sleep has major impacts on health economics" is centered over the map.

Poor sleep has major impacts on health economics

A blue circle containing the text "80%".

80%

A blue rectangular box containing the text "Number of sleep apnoea sufferers understood to be out of care right now".

Number of sleep apnoea sufferers understood to be out of care right now

An orange circle containing the text "\$26.2 BILLION".

\$26.2
BILLION

An orange rectangular box containing the text "Financial losses in Australia between 2016-2017 from inadequate sleep".

Financial losses in Australia between 2016-2017 from inadequate sleep

A dark blue circle containing the text "\$40.1 BILLION".

\$40.1
BILLION

A dark blue rectangular box containing the text "Australia attributed \$40.1 billion to loss of well-being in 2016-2017".


Australia attributed \$40.1 billion to loss of well-being in 2016-2017

The big business of sleep

A photograph of a young woman and a young man lying in bed. The woman is on the left, sleeping with her mouth wide open, indicating she may have sleep apnea. The man is on the right, looking upwards with a concerned expression. They are both under a light blue and white striped blanket.

Obstructive Sleep Apnoea (OSA) is an extensive market. It is worth A\$3.8bn** globally, growing at a CAGR of 15-20%.

** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98.



Only 20% of OSA sufferers
are in care.


Why?

Their inability to tolerate
conventional treatment.



Does this look comfortable to you?

Our titanium, 3D printed airway technology “O₂Vent™” enhances treatment outcomes **for more than 50%** of OSA patients



O₂Vent™ device:
in market

* Refer to OVEN-003 Brisbane clinical trial results, announced 22nd May 2018: <http://oventus.com.au/investors/asx-announcements/>



When added to our “O₂Vent™”, our valve technology enhances treatment outcomes, meaning we can now treat **more than 75%*** of OSA patients

Oventus ExVent™ oral PEEP valve: expected in market, Q4 CY2018

* Refer to NeuRA Sydney interim trial results, announced 29th May 2018: <http://oventus.com.au/investors/asx-announcements/>

Our valves combined with Oventus Airway Technology - truly bridging the gap between oral appliances and CPAP



O₂Vent™ ONEPAP™ (oro-nasal ePAP) valve:
in late stage development

* Refer to NeuRA Sydney interim trial results, announced 29th May 2018: <http://oventus.com.au/investors/asx-announcements/>

A close-up photograph of a man with dark hair and a beard sleeping in a bed. He is wearing a white chin strap device that is secured around his head and under his chin. The device appears to be designed to keep the mouth closed during sleep. He is wearing a blue long-sleeved shirt. The background shows a white pillow and a white blanket.

Without the need
for a CPAP mask

How Oventus Airway technology works

The O₂Vent™ technology is the first major innovation in the treatment of sleep apnoea for years

1.

Air goes in through the duckbill on inhalation and out on exhalation.



2.

Air travels through the channel and delivered to the back of the throat.

3.

Simultaneously, the device is adjustable, bringing the lower jaw forward and stabilising the airway

The duckbill acts as a “second nose”. Especially beneficial for patients with nasal blockage that forces them to mouth breathe. An open mouth is undesirable when sleeping, as an open jaw can cause breathing obstruction in the throat.

How the Oventus Airway with added PEEP valve technology works

The O₂Vent™ technology is the first major innovation in the treatment of sleep apnoea for years

4.


The placement of the valve in the duckbill promotes positive end-expiratory pressure (PEEP).



5.

Pressure builds up here to further stabilise the airway

Optima™ – the lighter brighter alternative



O₂Vent™ Optima device with ExVent™ and ONEPAP™: Optima in market Q4 CY2018, bringing faster turnaround times and reduced cost of goods



Compelling clinical data

In clinical trials (and in real life) our devices succeeded where others could not.

Oventus Airway Technology:

- Increases oral appliance efficacy by 30-50%
- Treats over 75% of patients without the need for CPAP
- Reduces CPAP pressures and eliminates the need for masks
- Delivers competitive advantages for half of the current oral appliance and mask market [A\$3.8bn per year].



>75%

Patients
successfully
treated their sleep
apnoea without
using CPAP



100%

Patients Treated
without using a full
face mask




100%

Patients
experienced
significant
improvement in
snoring using
O₂Vent

More patients are achieving success* with minimal intervention

Traditional lower jaw advancement (competitor products)	Oventus O ₂ Vent™	Oventus O ₂ Vent™ + EPAP	Oventus O ₂ Vent™ + Connect
Mandibular advancement splints			
41% ¹ of patients treated successfully	54% ¹ of patients treated successfully	78% ² of patients treated successfully	100% ³ of patients treated successfully

Cumulative Treatment Success Using Oventus treatment Platform (AHI ≤ 10 & >50% Reduction)



1. Karen McCloy, Damian Lavery, Julia Moldavtsev, Airway open-airway closed: The effect of mandibular advancement therapy for obstructive sleep apnoea with and without a novel in-built airway. Abstract Submitted ASA Brisbane 2018

2. Victor Lai, Benjamin Tong, Carolin Tran, Andrea Ricciardiello, Michelle Donegan, Nicholas Murray, Jayne Carberry and Danny Eckert Combination therapy with mandibular advancement and expiratory positive airway pressure valves reduces OSA severity. Abstract Submitted ASA Brisbane 2018

3. Amatoury J, Tong B, Nguyen C, Szollosi I, Eckert DJ THE ROLE OF A NOVEL ORAL APPLIANCE THERAPY DEVICE ON PHARYNGEAL PRESSURE SWINGS AND CPAP REQUIREMENTS DURING SLEEP IN OBSTRUCTIVE SLEEP APNEA: A PILOT STUDY. Abstract Supplement ADSM Boston 2017

* Traditional Jaw Advancement mouth guard

* AHI < 10 and 50% reduction

Oventus personalised Sleep Treatment Platform

..set to deliver treatment to **all types** of OSA patients,
potentially displacing the need for CPAP

Oventus
O₂Vent™



In market

Oventus
O₂Vent™ + ExVent™
oral EPAP



Expected to be released in
Q4 CY2018

Oventus
O₂Vent™ + ONEPAP™
oral/nasal EPAP



In late stage development

Oventus
O₂Vent™ Connect
CPAP connection



In late stage development



U.S. Sales and Marketing Strategies



Team Oventus USA - managing dental sleep initiatives



Robin Randolph

Accomplished Marketing & Sales executive 30+ years in the Sleep Industry. In-depth North America medical device commercialisation experience; product management, clinical education, reimbursement, & sales. Sleep Center operations management experience.



Peggy Powers

Experienced clinical educator and authority in the sleep & respiratory industry. Registered Respiratory Therapist 20+ years. Highly skilled in the design and delivery of comprehensive training programs for health care providers. Frequent presenter/educator.



Greg Eaton

Experienced medical device sales executive with 20+ years working within Sleep & Respiratory medical device markets. Possess keen innovative insights in the area of executing sales tactics, sales team development & forecasting. Multi-time recognised Presidents Club Achievement awardee for outstanding sales performance.




Brian Ueda

Skillful marketing manager with an innate ability to take complex technical ideas and distill them into user-friendly visuals to drive marketing campaigns. Experienced in traditional advertising, marketing, graphic design & film.



Robyn Woidtke

Credentialed in Clinical Sleep Health with a sleep medicine career spanning 30+ years and experience in the medical device industry spanning 20+ years. Patient focused in approach. Roles combining research, education and regulation.



Medical Technology Advisory Board



Dr. Lee A. Surkin, MD, FAASM
Chief Medical Officer of N3Sleep



Dr. Mark A. Rasmus, MD, FAASM
Medical Director, Idaho Sleep Health



Dr. Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor at the University of South Carolina School of Medicine in Columbia, SC and Medical University of SC in Charleston, SC



Daniel B. Brown, Esq.
Partner, Healthcare and Corporate Practice Groups, Taylor English Duma LLP Atlanta, Georgia



Jerrold A. Kram, MD, FCCP, FAASM
Medical Director of the California Centre for Sleep Disorders




Myra G. Brown
President, MbrownGroup LLC



Dr. Mark Hickey, MD, FAASM
Founder, Colorado Sleep Institute

Distribution agreement with Modern Dental Group... the world's largest distributor of dental prosthetics

MODERN DENTAL GROUP LOCATIONS



Modern Dental is listed on HKSE

Ticker: 3600 | Market cap: \$2.21 b

Has 25% coverage of all dentists in USA
(34,000 dental offices through subsidiary,
Microdental)

Top 3 market share in all major European
countries

Australia's largest dental laboratory network

70+ sales and customer service centres
overseas

Focus on custom-made prostheses

Oventus' range is **the only premium device range** that Modern will sell



Business Models

Corporate Hybrid

Hospital Owned

Physician Owned

Managed Service
Organization

Sales Channels

Sleep Hybrids & Labs

Discussions with Largest Performing >500,000 sleep studies per year



Direct To Consumer

CPAP Rescue
Call to action voucher for 3D scan

Dental Service Organizations

Targeting 4 that manage >30,000 Practices combined & located in 33 states



Veterans Administration

Identify distributor with Federal Supply Schedule



Appliance validation - O₂Vent (Oventus Airway Technology)

Clinical trials validate Oventus 'airway technology' and assist marketing

Name	Study/Investigation	Patients completed (per Oct 2018)	Results - reduction in AHI (sleep events per hour)**	Commentary	Peer review / events
Sydney study (NeuRa) OVEN-005 CRC-P funded (\$2.95m) 3 stages over 3 years 180 Patients in Total	Pilot study	4	37 reduced to 8 = 78% reduction Airway Technology increased efficacy by 50% compared to traditional oral appliance	In addition to AHI reduction, 66% reduction in CPAP pressure required when using Oventus CPAP connector	Presented at AADSM/AASM Sleep 2017 in Boston
	Nasal Resistance Study	7	34.4 reduced to 7.0 = 80% reduction	Increased nasal resistance did not impact treatment outcomes	Interim results presented at Prague, World Sleep Congress (abstract) 9-12 October 2017
		39	29 reduced to 14.5 = 50% reduction		Expanded results presented at European Respiratory Society in Paris September 2018
	PEEP Valve Study	13*	30.5 reduced to 16.4 In previous treatment failures	Success rates increased by 58% enabling over 75% of patients to be treated successfully without CPAP	Final results being presented at the ASA Sleep DownUnder conference, October 2018
	MAS Combo Study	16	CPAP pressure requirements reduced by 35-40%	Patients able to breathe through the device while using nasal CPAP eliminating the need for full face masks	Interim results presented at European Respiratory Society (ERS) in Paris September 2018 Expanded results being presented at Sleep DownUnder Conference in October 2018

* Results from a further 9 patients to be presented at the ASA Sleep DownUnder conference in October 2018 – results not publicly available yet

** Apnoea-Hypopnoea Index (AHI), known as 'sleep events' per hour occurring when the breathing airway collapses temporarily, leading to disruptions in breathing and sleep, in patients with Obstructive Sleep Apnoea (OSA)

Appliance validation - O₂Vent (Oventus Airway Technology)

Clinical trials validate Oventus 'airway technology' and assist marketing

Name	Study/Investigation	Patients completed (per Oct 2018)	Results - reduction in AHI (sleep events per hour)**	Commentary	Peer review / events
Perth study OVEN-004	Effect of Oventus Airway on Upper airway Physiology	10*	69.6 reduced to 19.4 = 72% reduction	Airway Technology increased Efficacy by 30%	Interim results: Auckland Sleep Down Under, ASA Conference (abstract) 25 October 2017
Brisbane study OVEN-003	Effect of Oventus Airway on Efficacy and Compliance	32	24 reduced to 10 = 58% reduction	Airway Technology increased response rate by 40% and success rate by 20% Increased efficacy in nasal obstructers and previous treatment failures	Final results being presented at the ASA Sleep Down Under Oct 2018
Brisbane study OVEN-001	Efficacy of Oventus O ₂ Vent	29	42 reduced to 16 = 62.5% reduction	Same response rate and efficacy with and without self reported nasal congestion	Journal of Dental Sleep Medicine, Vol 4, No. 3
Total patients		150			

* Results from a further 13 patients to be presented at the ASA Sleep DownUnder conference in October 2018 – results not publicly available yet

** Apnoea-Hypopnoea Index (AHI), known as 'sleep events' per hour occurring when the breathing airway collapses temporarily, leading to disruptions in breathing and sleep, in patients with Obstructive Sleep Apnoea (OSA)

Corporate snapshot

Oventus Medical Limited: ASX:OVN

Capital Structure

Shares on issue	105.94m
Price (5/10/2018)	\$0.31
Market Cap (5/10/2018)	\$30.72m
Options	4.27m
Cash on hand (30/6/2018)	\$9.90m
Revenue FY2018	\$271.32k



Investment summary

Oventus is driving the most significant change the sleep apnoea market has seen for years

- Oventus Airway Technology and valve accessories set to disrupt a large and growing market
- Recent data shows that over 75% of patients can be treated without the need for CPAP*
- Clinical evidence is further building, supported by ongoing clinical trials
- Driving dental channel sales, underpinned by Modern Dental distribution agreement
- Building interest in much larger sleep channel, with early adopters driving for change
- OSA market is extensive: A\$3.8bn per year, growing at 15-20% CAGR**, with only 20% of OSA sufferers in care
- Strong institutional investor support and balance sheet

* Refer to NeuRA Sydney interim trial results, announced 29th May 2018: <http://oventus.com.au/investors/asx-announcements>; CPAP machine: Continuous Positive Airway Pressure machine. Examples include by ResMed, Fisher & Paykel, and Phillips Respironics

** In 2015: Sleep Apnea Diagnostic & Therapeutic Devices Market, Markets and Markets, Table 98



“I HAVE USED THE OVENTUS DEVICE FOR 3 YEARS AND IT IS AMAZING.

No snoring and so easy to carry around. Used it right through Europe and did not have to worry about electricity or extra bags. Used a CPAP for 20 years. Now I am so free from all that. I love it!”

Jeanne Marshall

See more at www.oventus.com.au